Compare ATRO & HAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATRO | HAE |
|---|---|---|
| Founded | 1968 | 1971 |
| Country | United States | United States |
| Employees | 2700 | N/A |
| Industry | Military/Government/Technical | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.8B |
| IPO Year | N/A | 1996 |
| Metric | ATRO | HAE |
|---|---|---|
| Price | $84.31 | $67.26 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $86.00 | $84.13 |
| AVG Volume (30 Days) | 528.1K | ★ 809.4K |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.05 |
| Revenue | N/A | ★ $910,373,000.00 |
| Revenue This Year | $14.92 | N/A |
| Revenue Next Year | $8.81 | $5.23 |
| P/E Ratio | ★ N/A | $31.78 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $27.27 | $47.32 |
| 52 Week High | $86.27 | $87.32 |
| Indicator | ATRO | HAE |
|---|---|---|
| Relative Strength Index (RSI) | 61.27 | 70.38 |
| Support Level | $70.70 | $49.26 |
| Resistance Level | N/A | $86.72 |
| Average True Range (ATR) | 4.55 | 3.39 |
| MACD | 0.45 | 1.31 |
| Stochastic Oscillator | 87.43 | 98.78 |
Astronics Corporation is a provider of technologies to the aerospace, defense, and electronics industries, offering high-performance electrical power generation and distribution systems, motion systems, lighting and safety systems, avionics products, systems certification, aircraft structures, and automated test systems. The company operates through two reportable segments, Aerospace and Test Systems. The Aerospace segment designs and manufactures products for the aerospace and defense industry and generates the majority of revenue, while the Test Systems segment designs, develops, manufactures, and maintains automated test systems for the aerospace and defense, communications, and mass transit industries. The company derives the majority of its revenue from the United States.
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.